Therapeutic targeting of diabetic retinal neuropathy as a strategy in preventing diabetic retinopathy

Clinical and Experimental Ophthalmology

Volumn 44, Issue 9, 2016, Pages 838-852

  de Moraes, Gabriela ^a   Layton, Christopher J ^b,c,d  

^a FACULDADE DE MEDICINA DE MARÍLIA   (Brazil)

^b Gallipoli Medical Research Centre   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d GREENSLOPES PRIVATE HOSPITAL   (Australia)

Author keywords

diabetes; diabetic complications; diabetic retinal neuropathy; diabetic retinopathy; treatment

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AGENTS ACTING ON THE EYE; ALDOSE REDUCTASE INHIBITOR; ANTIOXIDANT; ENZYME INHIBITOR; ERYTHROPOIETIN; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; INSULIN; NEUROTROPHIC FACTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE INHIBITOR; SIRTUIN 1; SIRTUIN 1 ACTIVATOR; THIOREDOXIN; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT;

APOPTOSIS; BLINDNESS; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DARK ADAPTATION; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; ELECTRORETINOGRAPHY; EXPERIMENTAL MODEL; GLAUCOMA; GLIA CELL; HUMAN; LABORATORY TEST; METABOLIC PARAMETERS; MICROANGIOPATHY; NERVE CELL NECROSIS; NERVE CELL STIMULATION; NERVE INJURY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PERIMETRY; PSYCHOPHYSICS; RETINA NERVE CELL; RETINAL METABOLIC DEMAND; REVIEW; TRANSLATIONAL RESEARCH; VASCULAR DISEASE; VISUAL SYSTEM PARAMETERS; ANIMAL; COLOR VISION DEFECTS; CONTRAST SENSITIVITY; DIABETIC NEUROPATHIES;

ANIMALS; COLOR VISION DEFECTS; CONTRAST SENSITIVITY; DARK ADAPTATION; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; ELECTRORETINOGRAPHY; FENOFIBRATE; HUMANS; HYPOLIPIDEMIC AGENTS; VISUAL FIELD TESTS;

EID: 84980007101     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/ceo.12795     Document Type: Review

References (197)

1. Yau JW, Rogers SL, Kawasaki R, et al. Meta-analysis for eye disease study G. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012; 35: 556–64.
2. JR A. Epidemiology. In: JG C-V, ed. Epidemiology. Singapore: Wold Scientific, 2011; 165–99.
3. West SK, Rubin GS, Broman AT, Munoz B, Bandeen-Roche K, Turano K. How does visual impairment affect performance on tasks of everyday life? The SEE Project. Salisbury Eye Evaluation. Arch Ophthalmol 2002; 120: 774–80.
4. Daien V, Peres K, Villain M, Colvez A, Carriere I, Delcourt C. Visual acuity thresholds associated with activity limitations in the elderly. The Pathologies Oculaires Liees a l'age study. Acta Ophthalmol 2014; 92: e500–6.
5. Nguyen QD, Shah SM, Heier JS, et al. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2009; 116: 2175–81 e1.
6. Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2010; 117: 2146–51.
7. Bouchardat A. Nouveau memoire sur la glycosurie. Ann de Therap Suppl 1846; 162–311.
8. Manz W. Retinitis proliferans. Graefes Arch Clin Exp Ophthalmol 1876; 22: 229.
9. Ballantyne AJ, Loewenstein A. Retinal micro-aneurysms and punctate haemorrhages. Br J Ophthalmol 1944; 28: 593–8.
10. Wolter JR. Diabetic retinopathy. Am J Ophthalmol 1961; 51: 1123–39.
11. Bloodworth JMB. Diabetic retinopathy. Diabetes 1962; 2: 1–22.
12. Ashton N. Arteriolar involvement in diabetic retinopathy. Br J Ophthalmol 1953; 37: 282–92.
13. Ashton N. Diabetic retinopathy: a new approach. Lancet 1959; 2: 625–30.
14. Ashton N. Studies of the Retinal Capillaries in Relation to Diabetic and Other Retinopathies. Br J Ophthalmol 1963; 47: 521–38.
15. Caldwell G, Kohner EM. Diabetic retinopathy and nephropathy--are they related? J Diabet Complications 1989; 3: 137–8.
16. Lieth E, Gardner TW, Barber AJ, Antonetti DA, Penn State Retina Research G. Retinal neurodegeneration: early pathology in diabetes. Clin Experiment Ophthalmol 2000; 28: 3–8.
17. Layton CJ, Wood JP, Chidlow G, Osborne NN. Neuronal death in primary retinal cultures is related to nitric oxide production, and is inhibited by erythropoietin in a glucose-sensitive manner. J Neurochem 2005; 92: 487–93.
18. Layton CJ, Chidlow G, Casson RJ, Wood JP, Graham M, Osborne NN. Monocarboxylate transporter expression remains unchanged during the development of diabetic retinal neuropathy in the rat. Invest Ophthalmol Vis Sci 2005; 46: 2878–85.
19. Adams AJ, Bearse MA Jr. Retinal neuropathy precedes vasculopathy in diabetes: a function-based opportunity for early treatment intervention? Clin Exp Optom 2012; 95: 256–65.
20. Han Y, Bearse MA Jr, Schneck ME, Barez S, Jacobsen CH, Adams AJ. Multifocal electroretinogram delays predict sites of subsequent diabetic retinopathy. Invest Ophthalmol Vis Sci 2004; 45: 948–54.
21. Ng JS, Bearse MA Jr, Schneck ME, Barez S, Adams AJ. Local diabetic retinopathy prediction by multifocal ERG delays over 3 years. Invest Ophthalmol Vis Sci 2008; 49: 1622–8.
22. Layton C. Aspects of Diabetic Retinal Neuropathy. In: Aspects of Diabetic Retinal Neuropathy. Oxford, UK: Oxford University, 2006.
23. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370: 1687–97.
24. Chew EY, Davis MD, Danis RP, et al. Action to control cardiovascular risk in diabetes eye study research G. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the action to control cardiovascular risk in diabetes (ACCORD) eye study. Ophthalmology 2014; 121: 2443–51.
25. Birch DG, Anderson JL. Standardized full-field electroretinography. Normal values and their variation with age. Arch Ophthalmol 1992; 110: 1571–6.
26. Sieving PA, Murayama K, Naarendorp F. Push-pull model of the primate photopic electroretinogram: a role for hyperpolarizing neurons in shaping the b-wave. Vis Neurosci 1994; 11: 519–32.
27. Marmor MF, Holder GE, Seeliger MW, Yamamoto S, International Society for Clinical Electrophysiology of V. Standard for clinical electroretinography (2004 update). Doc Ophthalmol 2004; 108: 107–14.
28. Wachtmeister L. Oscillatory potentials in the retina: what do they reveal. Prog Retin Eye Res 1998; 17: 485–521.
29. Simonsen SE. The value of the oscillatory potential in selecting juvenile diabetics at risk of developing proliferative retinopathy. Acta Ophthalmol (Copenh) 1980; 58: 865–78.
30. Frost-Larsen K, Larsen HW, Simonsen SE. Oscillatory potential and nyctometry in insulin-dependent diabetics. Acta Ophthalmol (Copenh) 1980; 58: 879–88.
31. Layton CJ, Safa R, Osborne NN. Oscillatory potentials and the b-Wave: partial masking and interdependence in dark adaptation and diabetes in the rat. Graefe's Arch Clin Exp Ophthalmol 2007; 245: 1335–45.
32. Han Y, Schneck ME, Bearse MA Jr, et al. Formulation and evaluation of a predictive model to identify the sites of future diabetic retinopathy. Invest Ophthalmol Vis Sci 2004; 45: 4106–12.
33. Bresnick GH, Korth K, Groo A, Palta M. Electroretinographic oscillatory potentials predict progression of diabetic retinopathy. Arch Ophthalmol 1984; 102: 1307–11.
34. Segawa M, Hirata Y, Fujimori S, Okada K. The development of electroretinogram abnormalities and the possible role of polyol pathway activity in diabetic hyperglycemia and galactosemia. Metabolism 1988; 37: 454–60.
35. Bearse MA Jr, Ozawa GY. Multifocal electroretinography in diabetic retinopathy and diabetic macular edema. Curr Diab Rep 2014; 14: 526.
36. Harrison WW, Bearse MA Jr, Ng JS, et al. Multifocal electroretinograms predict onset of diabetic retinopathy in adult patients with diabetes. Invest Ophthalmol Vis Sci 2011; 52: 772–7.
37. Aylward GW. The scotopic threshold response in diabetic retinopathy. Eye 1989; 3: 626–37.
38. Afrashi F, Erakgun T, Kose S, Ardic K, Mentes J. Blue-on-yellow perimetry versus achromatic perimetry in type 1 diabetes patients without retinopathy. Diabetes Res Clin Pract 2003; 61: 7–11.
39. Mandlebaum J. Dark adaptation; physiologic and clinical considerations. Arch Ophthalmol 1941; 26: 203–39.
40. Neckell A. Adaptometry in diabetic patients. Oftalmologia 2007; 51: 95–7.
41. Arden GB, Wolf JE, Tsang Y. Does dark adaptation exacerbate diabetic retinopathy? Evidence and a linking hypothesis. Vision Res 1998; 38: 1723–9.
42. Hyvarinen L, Laurinen P, Rovamo J. Contrast sensitivity in evaluation of visual impairment due to diabetes. Acta Ophthalmol (Copenh) 1983; 61: 94–101.
43. Harris A, Arend O, Danis RP, Evans D, Wolf S, Martin BJ. Hyperoxia improves contrast sensitivity in early diabetic retinopathy. Br J Ophthalmol 1996; 80: 209–13.
44. Stavrou EP, Wood JM. Letter contrast sensitivity changes in early diabetic retinopathy. Clin Exp Optom 2003; 86: 152–6.
45. Daley ML, Watzke RC, Riddle MC. Early loss of blue-sensitive color vision in patients with type I diabetes. Diabetes Care 1987; 10: 777–81.
46. Roy MS, Gunkel RD, Podgor MJ. Color vision defects in early diabetic retinopathy. Arch Ophthalmol 1986; 104: 225–8.
47. Hellgren KJ, Agardh E, Bengtsson B. Progression of early retinal dysfunction in diabetes over time: results of a long-term prospective clinical study. Diabetes 2014; 63: 3104–11.
48. Hammes HP, Federoff HJ, Brownlee M. Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Mol Med 1995; 1: 527–34.
49. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 1998; 102: 783–91.
50. Park SH, Park JW, Park SJ, et al. Apoptotic death of photoreceptors in the streptozotocin-induced diabetic rat retina. Diabetologia 2003; 46: 1260–8.
51. Aizu Y, Oyanagi K, Hu J, Nakagawa H. Degeneration of retinal neuronal processes and pigment epithelium in the early stage of the streptozotocin-diabetic rats. Neuropathology 2002; 22: 161–70.
52. Kern TS, Barber AJ. Retinal ganglion cells in diabetes. J Physiol 2008; 586: 4401–8.
53. Zeng XX, Ng YK, Ling EA. Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Vis Neurosci 2000; 17: 463–71.
54. van Dijk HW, Kok PH, Garvin M, et al. Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy. Invest Ophthalmol Vis Sci 2009; 50: 3404–9.
55. van Dijk HW, Verbraak FD, Stehouwer M, et al. Association of visual function and ganglion cell layer thickness in patients with diabetes mellitus type 1 and no or minimal diabetic retinopathy. Vision Res 2011; 51: 224–8.
56. Araszkiewicz A, Zozulinska-Ziolkiewicz D, Meller M, et al. Neurodegeneration of the retina in type 1 diabetic patients. Pol Arch Med Wewn 2012; 122: 464–70.
57. Lonneville YH, Ozdek SC, Onol M, Yetkin I, Gurelik G, Hasanreisoglu B. The effect of blood glucose regulation on retinal nerve fiber layer thickness in diabetic patients. Ophthalmologica 2003; 217: 347–50.
58. van Dijk HW, Verbraak FD, Kok PH, et al. Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes. Invest Ophthalmol Vis Sci 2010; 51: 3660–5.
59. Fukuda M, Nakanishi Y, Fuse M, et al. Altered expression of aquaporins 1 and 4 coincides with neurodegenerative events in retinas of spontaneously diabetic Torii rats. Exp Eye Res 2010; 90: 17–25.
60. Barber AJ, Antonetti DA, Gardner TW. Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. The penn state retina research group. Invest Ophthalmol Vis Sci 2000; 41: 3561–8.
61. Lieth E, Barber AJ, Xu B, et al. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Diabetes 1998; 47: 815–20.
62. Mizutani M, Gerhardinger C, Lorenzi M. Muller cell changes in human diabetic retinopathy. Diabetes 1998; 47: 445–9.
63. Layton CJ, Becker S, Osborne NN. The effect of insulin and glucose levels on retinal glial cell activation and pigment epithelium-derived fibroblast growth factor-2. Mol Vis 2006; 12: 43–54.
64. Vujosevic S, Micera A, Bini S, Berton M, Esposito G, Midena E. Aqueous humor biomarkers of muller cell activation in diabetic eyes. Invest Ophthalmol Vis Sci 2015; 56: 3913–8.
65. Kumar B, Gupta SK, Nag TC, et al. Retinal neuroprotective effects of quercetin in streptozotocin-induced diabetic rats. Exp Eye Res 2014; 125: 193–202.
66. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res 2007; 2007: 95103.
67. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res 2011; 30: 343–58.
68. Hauk TG, Muller A, Lee J, Schwendener R, Fischer D. Neuroprotective and axon growth promoting effects of intraocular inflammation do not depend on oncomodulin or the presence of large numbers of activated macrophages. Exp Neurol 2008; 209: 469–82.
69. Zeng HY, Green WR, Tso MO. Microglial activation in human diabetic retinopathy. Arch Ophthalmol 2008; 126: 227–32.
70. Barber AJ, Antonetti DA, Kern TS, et al. The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci 2005; 46: 2210–8.
71. Krady JK, Basu A, Allen CM, et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 2005; 54: 1559–65.
72. Chen Y, Hu Y, Zhou T, et al. Activation of the Wnt pathway plays a pathogenic role in diabetic retinopathy in humans and animal models. Am J Pathol 2009; 175: 2676–85.
73. Vincent JA, Mohr S. Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes 2007; 56: 224–30.
74. Behl Y, Krothapalli P, Desta T, DiPiazza A, Roy S, Graves DT. Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am J Pathol 2008; 172: 1411–8.
75. Fogal B, Hewett SJ. Interleukin-1beta: a bridge between inflammation and excitotoxicity? J Neurochem 2008; 106: 1–23.
76. Abcouwer SF, Shanmugam S, Gomez PF, et al. Effect of IL-1beta on survival and energy metabolism of R28 and RGC-5 retinal neurons. Invest Ophthalmol Vis Sci 2008; 49: 5581–92.
77. Simo R, Hernandez C, European Consortium for the Early Treatment of Diabetic R. Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab 2014; 25: 23–33.
78. el-Remessy AB, Bartoli M, Platt DH, Fulton D, Caldwell RB. Oxidative stress inactivates VEGF survival signaling in retinal endothelial cells via PI 3-kinase tyrosine nitration. J Cell Sci 2005; 118: 243–52.
79. Du Y, Veenstra A, Palczewski K, Kern TS. Photoreceptor cells are major contributors to diabetes-induced oxidative stress and local inflammation in the retina. Proc Natl Acad Sci U S A 2013; 110: 16586–91.
80. Du Y, Sarthy VP, Kern TS. Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats. Am J Physiol Regul Integr Comp Physiol 2004; 287: R735–41.
81. Dorner GT, Garhofer G, Kiss B, et al. Nitric oxide regulates retinal vascular tone in humans. Am J Physiol Heart Circ Physiol 2003; 285: H631–6.
82. Kur J, Newman EA, Chan-Ling T. Cellular and physiological mechanisms underlying blood flow regulation in the retina and choroid in health and disease. Prog Retin Eye Res 2012; 31: 377–406.
83. Goureau O, Regnier-Ricard F, Courtois Y. Requirement for nitric oxide in retinal neuronal cell death induced by activated Muller glial cells. J Neurochem 1999; 72: 2506–15.
84. Kowluru RA, Chan PS. Oxidative stress and diabetic retinopathy. Exp Diabetes Res 2007; 2007: 43603.
85. Zhou J, Huang K. Peroxynitrite mediates muscle insulin resistance in mice via nitration of IRbeta/IRS-1 and Akt. Toxicol Appl Pharmacol 2009; 241: 101–10.
86. Sharma K. Mitochondrial hormesis and diabetic complications. Diabetes 2015; 64: 663–72.
87. Ramasamy R, Yan SF, Schmidt AM. Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci 2011; 1243: 88–102.
88. Chen M, Curtis TM, Stitt AW. Advanced glycation end products and diabetic retinopathy. Curr Med Chem 2013; 20: 3234–40.
89. Scivittaro V, Ganz MB, Weiss MF. AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am J Physiol Renal Physiol 2000; 278: F676–83.
90. Bikbova G, Oshitari T, Yamamoto S. Neurite regeneration in adult rat retinas exposed to advanced glycation end-products and regenerative effects of neurotrophin-4. Brain Res 2013; 1534: 33–45.
91. Dong N, Li X, Xiao L, Yu W, Wang B, Chu L. Upregulation of retinal neuronal MCP-1 in the rodent model of diabetic retinopathy and its function in vitro. Invest Ophthalmol Vis Sci 2012; 53: 7567–75.
92. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol 2008; 30: 65–84.
93. Lu J, Holmgren A. The thioredoxin antioxidant system. Free Radic Biol Med 2014; 66: 75–87.
94. Perrone L, Devi TS, Hosoya KI, Terasaki T, Singh LP. Inhibition of TXNIP expression in vivo blocks early pathologies of diabetic retinopathy. Cell Death Dis 2010; 1: e65.
95. Devi TS, Hosoya K, Terasaki T, Singh LP. Critical role of TXNIP in oxidative stress, DNA damage and retinal pericyte apoptosis under high glucose: implications for diabetic retinopathy. Exp Cell Res 2013; 319: 1001–12.
96. Devi TS, Lee I, Huttemann M, Kumar A, Nantwi KD, Singh LP. TXNIP links innate host defense mechanisms to oxidative stress and inflammation in retinal Muller glia under chronic hyperglycemia: implications for diabetic retinopathy. Exp Diabetes Res 2012; 2012: 438238.
97. El-Azab MF, Baldowski BR, Mysona BA, et al. Deletion of thioredoxin-interacting protein preserves retinal neuronal function by preventing inflammation and vascular injury. Br J Pharmacol 2014; 171: 1299–313.
98. Kim HC, Cho YJ, Ahn CW, et al. Nerve growth factor and expression of its receptors in patients with diabetic neuropathy. Diabet Med 2009; 26: 1228–34.
99. Mysona BA, Shanab AY, Elshaer SL, El-Remessy AB. Nerve growth factor in diabetic retinopathy: beyond neurons. Expert Rev Ophthalmol 2014; 9: 99–107.
100. Mysona BA, Al-Gayyar MM, Matragoon S, et al. Modulation of p75(NTR) prevents diabetes- and proNGF-induced retinal inflammation and blood-retina barrier breakdown in mice and rats. Diabetologia 2013; 56: 2329–39.
101. Al-Gayyar MM, Mysona BA, Matragoon S, et al. Diabetes and overexpression of proNGF cause retinal neurodegeneration via activation of RhoA pathway. PLoS One 2013; 8 e54692.
102. Atkinson J, Panni MK, Lund RD. Effects of neurotrophins on embryonic retinal outgrowth. Brain Res Dev Brain Res 1999; 112: 173–80.
103. Seki M, Tanaka T, Nawa H, et al. Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes 2004; 53: 2412–9.
104. Nitta A, Murai R, Suzuki N, et al. Diabetic neuropathies in brain are induced by deficiency of BDNF. Neurotoxicol Teratol 2002; 24: 695–701.
105. Oshitari T, Yoshida-Hata N, Yamamoto S. Effect of neurotrophin-4 on endoplasmic reticulum stress-related neuronal apoptosis in diabetic and high glucose exposed rat retinas. Neurosci Lett 2011; 501: 102–6.
106. Liu Y, Tao L, Fu X, Zhao Y, Xu X. BDNF protects retinal neurons from hyperglycemia through the TrkB/ERK/MAPK pathway. Mol Med Rep 2013; 7: 1773–8.
107. Aizu Y, Katayama H, Takahama S, Hu J, Nakagawa H, Oyanagi K. Topical instillation of ciliary neurotrophic factor inhibits retinal degeneration in streptozotocin-induced diabetic rats. Neuroreport 2003; 14: 2067–71.
108. Reiter CE, Wu X, Sandirasegarane L, et al. Diabetes reduces basal retinal insulin receptor signaling: reversal with systemic and local insulin. Diabetes 2006; 55: 1148–56.
109. Gordon WC, Bazan NG. Mediator lipidomics in ophthalmology: targets for modulation in inflammation, neuroprotection and nerve regeneration. Curr Eye Res 2013; 38: 995–1005.
110. Wang L, Deng QQ, Wu XH, Yu J, Yang XL, Zhong YM. Upregulation of glutamate-aspartate transporter by glial cell line-derived neurotrophic factor ameliorates cell apoptosis in neural retina in streptozotocin-induced diabetic rats. CNS Neurosci Ther 2013; 19: 945–53.
111. Deng H, Jin M, Yuan W, et al. A light and electron microscopy observation of diabetic retinopathy in rats. J Chin Jap Friend Hosp 2009; 2009: 350–2.
112. Schellini SA, Gregorio EA, Spadella CT, Machado JL, de-Moraes-Silva MA. Muller cells and diabetic retinopathy. Braz J Med Biol Res 1995; 28: 977–80.
113. Zhong Q, Kowluru RA. Diabetic retinopathy and damage to mitochondrial structure and transport machinery. Invest Ophthalmol Vis Sci 2011; 52: 8739–46.
114. Madsen-Bouterse SA, Mohammad G, Kanwar M, Kowluru RA. Role of mitochondrial DNA damage in the development of diabetic retinopathy, and the metabolic memory phenomenon associated with its progression. Antioxid Redox Signal 2010; 13: 797–805.
115. Alam NM, Mills WC, Wong AA, Douglas RM, Szeto HH, Prusky GT. A mitochondrial therapeutic reverses visual decline in mouse models of diabetes. Dis Model Mech 2015; 8: 701–10.
116. Kirby K, Hu J, Hilliker AJ, Phillips JP. RNA interference-mediated silencing of Sod2 in Drosophila leads to early adult-onset mortality and elevated endogenous oxidative stress. Proc Natl Acad Sci U S A 2002; 99: 16162–7.
117. Schulz TJ, Zarse K, Voigt A, Urban N, Birringer M, Ristow M. Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stress. Cell Metab 2007; 6: 280–93.
118. Dugan LL, You YH, Ali SS, et al. AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J Clin Invest 2013; 123: 4888–99.
119. Kang HM, Ahn SH, Choi P, et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med 2015; 21: 37–46.
120. Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 1997; 8: 159–66.
121. Arakawa R, Tamehiro N, Nishimaki-Mogami T, Ueda K, Yokoyama S. Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner. Arterioscler Thromb Vasc Biol 2005; 25: 1193–7.
122. Group AS, Group AES, Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363: 233–44.
123. Tomizawa A, Hattori Y, Inoue T, Hattori S, Kasai K. Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation. Metabolism 2011; 60: 513–22.
124. Noonan JE, Jenkins AJ, Ma JX, Keech AC, Wang JJ, Lamoureux EL. An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes 2013; 62: 3968–75.
125. Mann JF, Lonn EM, Yi Q, et al. Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. Kidney Int 2004; 65: 1375–80.
126. Williams M, Hogg RE, Chakravarthy U. Antioxidants and diabetic retinopathy. Curr Diab Rep 2013; 13: 481–7.
127. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37–46.
128. Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011; 365: 327–36.
129. Kowluru RA, Tang J, Kern TS. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes 2001; 50: 1938–42.
130. Aiello LP, Vignati L, Sheetz MJ, et al. Oral protein kinase c beta inhibition using Ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the protein kinase C beta inhibitor-diabetic retinopathy study and the protein kinase C beta inhibitor-diabetic retinopathy study 2. Retina 2011; 31: 2084–94.
131. Obrosova IG, Maksimchyk Y, Pacher P, et al. Evaluation of the aldose reductase inhibitor fidarestat on ischemia-reperfusion injury in rat retina. Int J Mol Med 2010; 26: 135–42.
132. Lee CA, Li G, Patel MD, et al. Diabetes-induced impairment in visual function in mice: contributions of p38 MAPK, rage, leukocytes, and aldose reductase. Invest Ophthalmol Vis Sci 2014; 55: 2904–10.
133. Sedeek M, Montezano AC, Hebert RL, et al. Oxidative stress, Nox isoforms and complications of diabetes--potential targets for novel therapies. J Cardiovasc Transl Res 2012; 5: 509–18.
134. Yokota H, Narayanan SP, Zhang W, et al. Neuroprotection from retinal ischemia/reperfusion injury by NOX2 NADPH oxidase deletion. Invest Ophthalmol Vis Sci 2011; 52: 8123–31.
135. Chen P, Guo AM, Edwards PA, Trick G, Scicli AG. Role of NADPH oxidase and ANG II in diabetes-induced retinal leukostasis. Am J Physiol Regul Integr Comp Physiol 2007; 293: R1619–29.
136. Kowluru RA, Kowluru A, Veluthakal R, et al. TIAM1-RAC1 signalling axis-mediated activation of NADPH oxidase-2 initiates mitochondrial damage in the development of diabetic retinopathy. Diabetologia 2014; 57: 1047–56.
137. Al-Shabrawey M, Bartoli M, El-Remessy AB, et al. Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy. Invest Ophthalmol Vis Sci 2008; 49: 3231–8.
138. Ali TK, Matragoon S, Pillai BA, Liou GI, El-Remessy AB. Peroxynitrite mediates retinal neurodegeneration by inhibiting nerve growth factor survival signaling in experimental and human diabetes. Diabetes 2008; 57: 889–98.
139. Mantelli F, Lambiase A, Colafrancesco V, Rocco ML, Macchi I, Aloe L. NGF and VEGF effects on retinal ganglion cell fate: new evidence from an animal model of diabetes. Eur J Ophthalmol 2014; 24: 247–53.
140. Zou MH, Li H, He C, Lin M, Lyons TJ, Xie Z. Tyrosine nitration of prostacyclin synthase is associated with enhanced retinal cell apoptosis in diabetes. Am J Pathol 2011; 179: 2835–44.
141. Osborne NN, Chidlow G, Layton CJ, Wood JP, Casson RJ, Melena J. Optic nerve and neuroprotection strategies. Eye (Lond) 2004; 18: 1075–84.
142. Osborne NN. Inhibition of cAMP production by alpha 2-adrenoceptor stimulation in rabbit retina. Brain Res 1991; 553: 84–8.
143. Chao HM, Osborne NN. Topically applied clonidine protects the rat retina from ischaemia/reperfusion by stimulating alpha(2)-adrenoceptors and not by an action on imidazoline receptors. Brain Res 2001; 904: 126–36.
144. Celiker U, Ilhan N, Ozercan I, Demir T, Celiker H. Octreotide reduces ischaemia-reperfusion injury in the retina. Acta Ophthalmol Scand 2002; 80: 395–400.
145. Hernandez C, Garcia-Ramirez M, Corraliza L, et al. Topical administration of somatostatin prevents retinal neurodegeneration in experimental diabetes. Diabetes 2013; 62: 2569–78.
146. Kusari J, Zhou SX, Padillo E, Clarke KG, Gil DW. Inhibition of vitreoretinal VEGF elevation and blood-retinal barrier breakdown in streptozotocin-induced diabetic rats by brimonidine. Invest Ophthalmol Vis Sci 2010; 51: 1044–51.
147. Gupta PC, Sood S, Narang S, Ichhpujani P. Role of brimonidine in the treatment of clinically significant macular edema with ischemic changes in diabetic maculopathy. Int Ophthalmol 2014; 34: 787–92.
148. Sena DF, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev 2013; 2 CD006539.
149. Kusari J, Zhou S, Padillo E, Clarke KG, Gil DW. Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci 2007; 48: 5152–9.
150. Arden GB, Sivaprasad S. The pathogenesis of early retinal changes of diabetic retinopathy. Doc Ophthalmol 2012; 124: 15–26.
151. Cao J, McLeod S, Merges CA, Lutty GA. Choriocapillaris degeneration and related pathologic changes in human diabetic eyes. Arch Ophthalmol 1998; 116: 589–97.
152. Arden GB, Jyothi S, Hogg CH, Lee YF, Sivaprasad S. Regression of early diabetic macular oedema is associated with prevention of dark adaptation. Eye (Lond) 2011; 25: 1546–54.
153. Sivaprasad S, Arden G, Prevost AT, et al. A multicentre phase III randomised controlled single-masked clinical trial evaluating the clinical efficacy and safety of light-masks at preventing dark-adaptation in the treatment of early diabetic macular oedema (CLEOPATRA): study protocol for a randomised controlled trial. Trials 2014; 15: 458.
154. McKeague C, Margrain TH, Bailey C, Binns AM. Low-level night-time light therapy for age-related macular degeneration (ALight): study protocol for a randomized controlled trial. Trials 2014; 15: 246.
155. Jacobson LO, Goldwasser E, Fried W, Plzak L. Role of the kidney in erythropoiesis. Nature 1957; 179: 633–4.
156. Eckardt KU. Biology of erythropoietin production. Nephrol Dial Transplant 1995; 10: 1572–4.
157. Marti HH, Gassmann M, Wenger RH, et al. Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain. Kidney Int 1997; 51: 416–8.
158. Marti HH, Wenger RH, Rivas LA, et al. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 1996; 8: 666–76.
159. Juul SE, Anderson DK, Li Y, Christensen RD. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 1998; 43: 40–9.
160. Grimm C, Wenzel A, Groszer M, et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med 2002; 8: 718–24.
161. Junk AK, Mammis A, Savitz SI, et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A 2002; 99: 10659–64.
162. Zhu B, Wang W, Gu Q, Xu X. Erythropoietin protects retinal neurons and glial cells in early-stage streptozotocin-induced diabetic rats. Exp Eye Res 2008; 86: 375–82.
163. Zhang J, Wu Y, Jin Y, et al. Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci 2008; 49: 732–42.
164. Li W, Sinclair SH, Xu GT. Effects of intravitreal erythropoietin therapy for patients with chronic and progressive diabetic macular edema. Ophthalmic Surg Lasers Imaging 2010; 41: 18–25.
165. Nystrom FH, Quon MJ. Insulin signalling: metabolic pathways and mechanisms for specificity. Cell Signal 1999; 11: 563–74.
166. Saltiel AR, Pessin JE. Insulin signaling pathways in time and space. Trends Cell Biol 2002; 12: 65–71.
167. Renehan AG, Shalet SM. Diabetes, insulin therapy, and colorectal cancer. BMJ 2005; 330: 551–2.
168. Bereket A, Lang CH, Wilson TA. Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus. Horm Metab Res 1999; 31: 172–81.
169. Havrankova J, Roth J, Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature 1978; 272: 827–9.
170. Waldbillig RJ, Fletcher RT, Chader GJ, Rajagopalan S, Rodrigues M, LeRoith D. Retinal insulin receptors. 2. Characterization and insulin-induced tyrosine kinase activity in bovine retinal rod outer segments. Exp Eye Res 1987; 45: 837–44.
171. Hedo JA, Kasuga M, Van Obberghen E, Roth J, Kahn CR. Direct demonstration of glycosylation of insulin receptor subunits by biosynthetic and external labeling: evidence for heterogeneity. Proc Natl Acad Sci U S A 1981; 78: 4791–5.
172. Rodrigues M, Waldbillig RJ, Rajagopalan S, Hackett J, LeRoith D, Chader GJ. Retinal insulin receptors: localization using a polyclonal anti-insulin receptor antibody. Brain Res 1988; 443: 389–94.
173. Stella SL Jr, Bryson EJ, Thoreson WB. Insulin inhibits voltage-dependent calcium influx into rod photoreceptors. Neuroreport 2001; 12: 947–51.
174. Rajala A, Dighe R, Agbaga MP, Anderson RE, Rajala RV. Insulin receptor signaling in cones. J Biol Chem 2013; 288: 19503–15.
175. Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care 1990; 13: 427–33.
176. Reiter CE, Gardner TW. Functions of insulin and insulin receptor signaling in retina: possible implications for diabetic retinopathy. Prog Retin Eye Res 2003; 22: 545–62.
177. Feldkaemper MP, Neacsu I, Schaeffel F. Insulin acts as a powerful stimulator of axial myopia in chicks. Invest Ophthalmol Vis Sci 2009; 50: 13–23.
178. Koevary SB, Nussey J, Kern TS. Long-term, topical insulin administration increases the severity of retinal vascular pathology in streptozotocin-induced diabetic rats. Optometry 2007; 78: 574–81.
179. Ristow M, Zarse K, Oberbach A, et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci U S A 2009; 106: 8665–70.
180. Ristow M, Zarse K. How increased oxidative stress promotes longevity and metabolic health: the concept of mitochondrial hormesis (mitohormesis). Exp Gerontol 2010; 45: 410–8.
181. Zid BM, Rogers AN, Katewa SD, et al. 4E-BP extends lifespan upon dietary restriction by enhancing mitochondrial activity in Drosophila. Cell 2009; 139: 149–60.
182. Lee SJ, Hwang AB, Kenyon C. Inhibition of respiration extends C. elegans life span via reactive oxygen species that increase HIF-1 activity. Curr Biol 2010; 20: 2131–6.
183. Mackenzie RM, Salt IP, Miller WH, et al. Mitochondrial reactive oxygen species enhance AMP-activated protein kinase activation in the endothelium of patients with coronary artery disease and diabetes. Clin Sci (Lond) 2013; 124: 403–11.
184. Kukidome D, Nishikawa T, Sonoda K, et al. Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 2006; 55: 120–7.
185. Ruderman NB, Cacicedo JM, Itani S, et al. Malonyl-CoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes. Biochem Soc Trans 2003; 31: 202–6.
186. Kemp BE, Stapleton D, Campbell DJ, et al. AMP-activated protein kinase, super metabolic regulator. Biochem Soc Trans 2003; 31: 162–8.
187. Roy Chowdhury SK, Smith DR, Saleh A, et al. Impaired adenosine monophosphate-activated protein kinase signalling in dorsal root ganglia neurons is linked to mitochondrial dysfunction and peripheral neuropathy in diabetes. Brain 2012; 135: 1751–66.
188. Yan W, Zhang H, Liu P, et al. Impaired mitochondrial biogenesis due to dysfunctional adiponectin-AMPK-PGC-1alpha signaling contributing to increased vulnerability in diabetic heart. Basic Res Cardiol 2013; 108: 329.
189. Yu X, Zhang L, Yang X, et al. Salvianolic acid A protects the peripheral nerve function in diabetic rats through regulation of the AMPK-PGC1alpha-Sirt3 axis. Molecules 2012; 17: 11216–28.
190. Kubota S, Ozawa Y, Kurihara T, et al. Roles of AMP-activated protein kinase in diabetes-induced retinal inflammation. Invest Ophthalmol Vis Sci 2011; 52: 9142–8.
191. Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118: 1645–56.
192. Wang Q, Gorbey S, Pfister F, et al. Long-term treatment with suberythropoietic Epo is vaso- and neuroprotective in experimental diabetic retinopathy. Cell Physiol Biochem 2011; 27: 769–82.
193. Hawley SA, Fullerton MD, Ross FA, et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 2012; 336: 918–22.
194. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167–74.
195. Al-Rasheed NM, Al-Rasheed NM, Attia HA, et al. Renoprotective Effects of Fenofibrate via Modulation of LKB1/AMPK mRNA Expression and Endothelial Dysfunction in a Rat Model of Diabetic Nephropathy. Pharmacology 2015; 95: 229–39.
196. Hong YA, Lim JH, Kim MY, et al. Fenofibrate improves renal lipotoxicity through activation of AMPK-PGC-1alpha in db/db mice. PLoS One 2014; 9 e96147.
197. Kowluru RA, Santos JM, Zhong Q. Sirt1, a negative regulator of matrix metalloproteinase-9 in diabetic retinopathy. Invest Ophthalmol Vis Sci 2014; 55: 5653–60.